Creative Biolabs have formed a portfolio of solutions to advance CAR-T therapies
Creative Biolabs has formed a portfolio of solutions to advance the creation of next-generation CAR-T cell therapies.
A spokesman for Creative Biolabs said, "Our goal is to provide researchers with innovative solutions that advance the innovation of CAR-T therapies. By integrating metabolic intelligence, functional precision, and end-to-end development services, we're building a platform for more sustainable and personalised cancer treatments."
Creative Biolabs provides a one-stop CAR-T therapy development platform spanning the whole lifecycle of therapeutic design, from CAR development and biomarker discovery to preclinical validation. The pipeline streamlines workflows, enabling T-cell engineering for rapid translation of research into effective therapies.
The platform includes:
- Smart CAR design for multi-antigen targeting
- mRNA-based CAR platforms for transient expression
- CRISPR-edited CAR cells for precision genome integration
These innovations are up-and-coming for solid tumour research, where conventional CAR-T therapies have previously struggled to achieve maintained efficacy.
The company has also acknowledged the metabolic challenges posed by the TME and established a metabolic optimisation program for CD8⁺ T cell optimisation. The program uses metabolomics to interpret and control the energy metabolism and survival pathways of tumour-infiltrating lymphocytes.
The company said, "Our metabolic immunoengineering services are designed to reboot the tumour-fighting capacity of T cells. By pairing metabolic fitness with immunotherapeutic strategy, we're revealing new axes of anti-tumour immunity."
Some of the primary services are:
- CD8⁺ T cell metabolic profiling and modulation
- Combination therapy development combining metabolic and CAR-T strategies
- Therapeutic evaluation platforms for therapies targeting metabolism
- Functional CAR-T discovery, beyond antigen affinity
Creative Biolabs has created a functional CAR-T discovery and development platform that highlights real-world performance metrics such as cytotoxicity, cytokine polyfunctionality, and exhaustion resistance.
One of the lead scientists at Creative Biolabs said, "Antigen binding is just the beginning. Therapeutic success ultimately depends on functional resilience; our platform is built to measure and enhance exactly that."
Some featured highlights include high-throughput functional screening with real-time killing assays, SynNotch and logic-gated CAR designs, and translational validation with humanised in vivo models.
